Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder

Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder - tolterodine for neurogenic detrusor overactivity

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037584

Enrollment

Registered

2020-03-31

Start date

2014-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurogenic bladder

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: neurogenic bladder

Exclusion criteria

Exclusion criteria: With an indwelling catheter, other genitourinary tract anomalies, acute infection of the genitourinary tract diseases

Design outcomes

Primary

Measure	Time frame
Changes in maximum cystometric capacity	—

Secondary

Measure	Time frame
Number of patients whose NDO disappeared after treatment, and changes in the urodynamic parameters, lower urinary tract questionnaires, and the frequency volume chart parameters	—

Countries

Japan

Contacts

Public ContactTomonori Yamanishi

Dokkyo Medical University Continence Center

yamanish@dokkyomed.ac.jp0282861111

Outcome results